Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masahiro Ikejiri is active.

Publication


Featured researches published by Masahiro Ikejiri.


Bioorganic & Medicinal Chemistry Letters | 2007

Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Masahiro Ikejiri; Masayuki Saijo; Shigeru Morikawa; Shuetsu Fukushi; Tetsuya Mizutani; Ichiro Kurane; Tokumi Maruyama

Abstract Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds, namely, 1 and 11, exhibited promising anti-SARS-CoV activity that was comparable to those of mizoribine and ribavirin, which are known anti-SARS-CoV agents. Moreover, we observed several SAR trends such as the antiviral effects of the 6-chloropurine moiety, unprotected 5′-hydroxyl group and benzoylated 5′-hydroxyl group.


Organic Letters | 2012

Design and Concise Synthesis of a Novel Type of Green Fluorescent Protein Chromophore Analogue

Masahiro Ikejiri; Moe Tsuchino; Yoshiko Chihara; Takao Yamaguchi; Takeshi Imanishi; Satoshi Obika; Kazuyuki Miyashita

A small molecular model compound for the green fluorescent protein chromophore was readily synthesized by a novel condensation reaction of (thio)imidate with imino-ester via an aziridine intermediate. This compound showed fluorescence in the solid and frozen solution states but not in the solution state. Its fluorescent property was successfully applied in the detection of dsDNA.


Antiviral Chemistry & Chemotherapy | 2011

Synthesis of 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives with potential anti-HIV activity

Yohei Isono; Norikazu Sakakibara; Paula Ordonez; Takayuki Hamasaki; Masanori Baba; Masahiro Ikejiri; Tokumi Maruyama

Background: Nine novel uracil analogues were synthesized and evaluated as inhibitors of HIV-1. Methods: Key structural modifications included replacement of the 6-chloro group of 1-benzyl-6-chloro-3-(3,5-dimethylbenzyl)uracil by other functional groups or N1-alkylation of 3-(3,5-dimethylbenzyl)-5-fluorouracil. Results: These compounds showed only micromolar potency against HIV-1 in MT-4, though two of them; 6-azido-1-benzyl-3-(3,5-dimethylbenzyl) uracil and 6-amino-1-benzyl-3-(3,5-dimethylbenzyl) uracil were highly potent (half maximal effective concentration =0.067 and 0.069 μM) and selective (selectivity index =685 and 661), respectively. Structure–activity relationships among the newly synthesized uracil analogues suggest the importance of the H-bond formed between 6-amino group of 6-amino-1-benzyl-3-(3,5-dimethylbenzyl) uracil and amide group of HIV-1 reverse transcriptase. Conclusions: We discovered two 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl) uracils, (6-azido-1-benzyl-3-(3,5-dimethylbenzyl) uracil and 6-amino-1-benzyl-3-(3,5-dimethylbenzyl) uracil) as novel anti-HIV agents. These compounds should be further pursued for their toxicity and pharmacokinetics in vivo as well as antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant strains.


Bioorganic & Medicinal Chemistry | 2007

5'-O-masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents.

Masahiro Ikejiri; Takayuki Ohshima; Keizo Kato; Masaaki Toyama; Takayuki Murata; Kunitada Shimotohno; Tokumi Maruyama

Abstract On the basis of our previous study on antiviral agents against the severe acute respiratory syndrome (SARS) coronavirus, a series of nucleoside analogues whose 5′-hydroxyl groups are masked by various protective groups such as carboxylate, sulfonate, and ether were synthesized and evaluated to develop novel anti-hepatitis C virus (HCV) agents. Among these, several 5′-O-masked analogues of 6-chloropurine-2′-deoxyriboside (e.g., 5′-O-benzoyl, 5′-O-p-methoxybenzoyl, and 5′-O-benzyl analogues) were found to exhibit effective anti-HCV activity. In particular, the 5′-O-benzoyl analogue exhibited the highest potency with an EC50 of 6.1μM in a cell-based HCV replicon assay. Since the 5′-O-unmasked analogue (i.e., 6-chloropurine-2′-deoxyriboside) was not sufficiently potent (EC50 =47.2μM), masking of the 5′-hydroxyl group seems to be an effective method for the development of anti-HCV agents. Presently, we hypothesize two roles for the 5′-O-masked analogues: One is the role as an anti-HCV agent by itself, and the other is as a prodrug of its 5′-O-demasked (deprotected) derivative.


Antimicrobial Agents and Chemotherapy | 2012

Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.

Paula Ordonez; Takayuki Hamasaki; Yohei Isono; Norikazu Sakakibara; Masahiro Ikejiri; Tokumi Maruyama; Masanori Baba

ABSTRACT Nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) are important components of current combination therapies for human immunodeficiency virus type 1 (HIV-1) infection. In screening of chemical libraries, we found 6-azido-1-benzyl-3-(3,5-dimethylbenzyl)uracil (AzBBU) and 6-amino-1-benzyl-3-(3,5-dimethylbenzyl)uracil (AmBBU) to be highly active and selective inhibitors of HIV-1 replication in vitro. To determine the resistance profiles of these compounds, we conducted a long-term culture of HIV-1-infected MT-4 cells with escalating concentrations of each compound. After serial passages of the infected cells, escape viruses were obtained, and they were more than 500-fold resistant to the uracil derivatives compared to the wild type. Sequence analysis was conducted for RT of the escape viruses at passages 12 and 24. The amino acid mutation Y181C in the polymerase domain of RT was detected for all escape viruses. Docking studies using the crystal structure of RT showed that AmBBU requires the amino acid residues Leu100, Val106, Tyr181, and Trp229 for exerting its inhibitory effect on HIV-1. Four additional amino acid changes (K451R, R461K, T468P, and D471N) were identified in the RNase H domain of RT; however, their precise role in the acquisition of resistance is still unclear. In conclusion, the initial mutation Y181C seems sufficient for the acquisition of resistance to the uracil derivatives AzBBU and AmBBU. Further studies are required to determine the precise role of each mutation in the acquisition of HIV-1 resistance.


Chemical Communications | 2002

Total synthesis of fostriecin (CI-920) via a convergent route

Kazuyuki Miyashita; Masahiro Ikejiri; Hitomi Kawasaki; Satoko Maemura; Takeshi Imanishi

Fostriecin, a potent and promising antitumor antibiotic, was stereoselectively synthesized via a convergent route involving a three-segement coupling procedure.


Organic and Biomolecular Chemistry | 2018

Synthesis and properties of geometrical 4-diarylmethylene analogs of the green fluorescent protein chromophore

Masahiro Ikejiri; Haruka Kojima; Yuumi Fugono; Aki Fujisaka; Yoshiko Chihara; Kazuyuki Miyashita

We have developed a novel analog of the GFP chromophore: geo-DAIN. Since geo-DAIN is equipped with an E/Z-photoisomerizable geometrical diarylmethylene moiety instead of benzylidene of the GFP chromophore, different-colored reversible emissions are expected. We synthesized geo-DAIN by a condensation with methyl imidate and N-(diarylmethylene)glycinate. We found the emission from geo-DAIN to be different from that of benzylidene-type analogs; in the powder state, the E- and Z-isomers of geo-DAIN emitted different fluorescence colors.


Journal of the American Chemical Society | 2003

Total Synthesis of Leustroducsin B

Kazuyuki Miyashita; Tomoyuki Tsunemi; Takafumi Hosokawa; Masahiro Ikejiri; Takeshi Imanishi


Journal of the American Chemical Society | 2003

Total synthesis of an antitumor antibiotic, fostriecin (CI-920)

Kazuyuki Miyashita; Masahiro Ikejiri; Hitomi Kawasaki; Satoko Maemura; Takeshi Imanishi


Tetrahedron Letters | 2007

Total synthesis of leustroducsin B via a convergent route

Kazuyuki Miyashita; Tomoyuki Tsunemi; Takafumi Hosokawa; Masahiro Ikejiri; Takeshi Imanishi

Collaboration


Dive into the Masahiro Ikejiri's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tokumi Maruyama

Tokushima Bunri University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takayuki Ohshima

Tokushima Bunri University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Akemi Fukushima

Tokushima Bunri University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge